Navigation Links
Braeburn Pharmaceuticals Applauds Repeal of HB2
Date:3/31/2017

PRINCETON, N.J., March 31, 2017 /PRNewswire/ -- Braeburn Pharmaceuticals, Inc. made the following statement today in response to the repeal of House Bill 2 (HB2).

"Diversity and a commitment to inclusion is core to the identity of Braeburn Pharmaceuticals. Last year, we decided to proceed with plans to develop a research facility in Durham County despite our deep concerns and opposition to HB2, vowing to do our part to help overturn it," said President and CEO Behshad Sheldon, Braeburn Pharmaceuticals. "We applaud Governor Cooper and legislative leaders for passing a compromise solution that removes HB2 and takes an important step to protect the rights of all citizens in North Carolina. We will continue to advocate for progressive public policy and support those who share our commitment to diversity and nondiscrimination."

About Braeburn Pharmaceuticals

Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in neuroscience. Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in neurological and psychiatric disorders, which are often complicated by stigma and present significant public health challenges. Braeburn's commercial product, Probuphine® (buprenorphine) implant was approved by the FDA in May 2016. Braeburn's investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Braeburn's pipeline products are at various stages of clinical development and include weekly and monthly CAM2038, subcutaneous injection depot formulations of buprenorphine, being investigated in opioid addiction and pain, BB0417 buprenorphine/granisetron injectable for acute pain, and BB0817, six-month risperidone implant being investigated in schizophrenia. More information on Braeburn can be found at www.braeburnpharmaceuticals.com.

Contacts:

Sherry Feldberg for Braeburn Pharmaceuticals
MSLGROUP
781-684-0770
braeburnpharma@mslgroup.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/braeburn-pharmaceuticals-applauds-repeal-of-hb2-300432936.html


'/>"/>
SOURCE Braeburn Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Fast Company Honors Braeburn Pharmaceuticals as a Top Ten Most Innovative Company in Biotech
2. Braeburn Pharmaceuticals and CEO Behshad Sheldon Win Stevie Awards for Best New Product or Service and Female Executive of the Year
3. Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain
4. Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval of Probuphine, First 6-Month Implant to Treat Opioid Addiction
5. Braeburn Pharmaceuticals and Camurus announces start of Phase 3 trial of long-acting buprenorphine treatments for opioid dependence
6. Braeburn Pharmaceuticals And Titan Pharmaceuticals Announce Date Of FDA Advisory Committee Review Of Probuphine For Opioid Addiction
7. Dr. Frank Young of Braeburn Pharmaceuticals Receives 2015 Distinguished Scientist Award from American College of Toxicology
8. Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments
9. Panacea Pharmaceuticals, Inc. Presents Data That Its Cancer Biomarker HAAH is Readily Detectable in Serum Exosomes
10. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Synergy Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
11. Glenmark Pharmaceuticals Reports Positive Results from a Phase 3 Trial of GSP 301, Mometasone/Olopatadine Fixed-Dose Combination Nasal Spray, in Seasonal Allergic Rhinitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2019)... ... ... RxNT announced today that it has been named by Software Advice ... a leader in healthcare technology solutions. This is the fourth time RxNT has received ... best software products from North American small businesses. RxNT won the FrontRunner mental health ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... of health to improve patient outcomes, recently announced the launch of its new ... and pharmacies to develop a customized, local network of community resources focused on ...
(Date:6/13/2019)... Pa. (PRWEB) , ... June 13, 2019 , ... ... organization in the northeastern United States, today announced the appointment of Frank Ingari ... directly to Chief Executive Officer Anthony Coletta, M.D., M.B.A. , With more ...
Breaking Medicine Technology:
(Date:6/13/2019)... NEW YORK (PRWEB) , ... ... ... of 3D printing—including medical and dental implants, additive manufacturing (AM)-enabled tissue fabrication, ... Every day, physicians are using AM medical technologies to improve patient care. ...
(Date:6/12/2019)... Va. (PRWEB) , ... June 12, 2019 , ... ... Andrea Miller, a quality assurance expert with more than 25 years of experience ... MDD Compliance for all classes of medical devices, has joined NDA Partners as ...
(Date:6/12/2019)... ... June 12, 2019 , ... We are excited ... for UPMC Pinnacle, a top-rated healthcare system, providing cutting-edge fertility treatment to patients ... for many premier insurance plans because of our commitment to evidence-based medicine and ...
(Date:6/11/2019)... ... 11, 2019 , ... Homecare Homebase (HCHB), the nation’s leader ... Management (RCM) service at the company’s annual Users Conference this week in Dallas. ... Services Suite, a collection of technology-enabled services designed to alleviate the burden associated ...
(Date:6/6/2019)... ... June 05, 2019 , ... ... the call for speaker proposals for its fourth annual Accountable Care Symposium on ... , The annual symposium brings together hundreds of health care leaders and providers ...
Breaking Medicine News(10 mins):